Literature DB >> 1565252

Acetazolamide treatment of paroxysmal dystonia in central demyelinating disease.

K D Sethi1, D C Hess, V H Huffnagle, R J Adams.   

Abstract

We report successful treatment of paroxysmal dystonia (tonic seizures) in three patients with central demyelinating disease (CDD) using acetazolamide alone or in combination with carbamazepine. Acetazolamide is a useful alternative, or an adjunct, to carbamazepine in the treatment of paroxysmal dystonia in CDD.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1565252     DOI： 10.1212/wnl.42.4.919

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  7 in total

1.  Long-term improvement of paroxysmal dystonic choreathetosis with acetazolamide.

Authors:  Veronique Michel; Florence Riant; Elisabeth Tournier-Lasserve; Dominique Guehl; Alain Lagueny; Bernard Bioulac; Pierre Burbaud
Journal:  J Neurol       Date:  2006-04-28       Impact factor: 4.849

2.  Paroxysmal Dyskinesia.

Authors:  Paul S. Fishman
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

Review 3.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Paroxysmal dystonia and paroxysmal tremor in a young patient with multiple sclerosis.

Authors:  N Nardocci; G Zorzi; M Savoldelli; V Rumi; L Angelini
Journal:  Ital J Neurol Sci       Date:  1995-06

5.  Paroxysmal dyskinesias.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

Review 6.  Medical treatment of dystonia.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2016-12-19

7.  Effect of acetazolamide for long-lasting paroxysmal dystonia in a patient with multiple sclerosis: a case report and review of literature.

Authors:  Pei-Chun Hsieh; Shu-Min Chen; Yao-Hong Guo; Ta-Shen Kuan; Wei-Jang Yen; Wen-Chen Chang; Yu-Ching Lin
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-04       Impact factor: 2.570
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.